Credit Suisse has released data describing how Pharmaceuticals is predicted to experience clinical trial readouts which could help ensure $74bn in top sales for this year.

Outside of Covid therapies, there were readouts to a value of $102bn in 2022 and $78bn in 2021.

“line extensions—drugs that have already received the go-ahead for application across different disease environments—will account for a record percentage of readouts this year“

According to the research, line extensions—drugs that have already received the go-ahead for application across different disease environments—will account for a record percentage of readouts this year—roughly 40%.

This especially aligns with key pharmaceutical businesses in Europe, where line expansions are anticipated to contribute 54% of the value, as opposed to 30% for key US pharma firms.

They also examined how different pharmaceutical businesses' NPVs may be affected by clinical and commercial catalysts.

Sanofi and GSK PLC are the companies with the highest total upside or downside, while Roche, Sanofi, AstraZeneca, and Novartis all had comparable 2-4% upside.

The UK equities for AstraVeneca and GSK, were depicted as "neutral" by the swiss bank.

Because of Roche and Sanofi's excellent development and potential increasing value, the bank kept their "outperform" ratings.

© Copyright 2010-2021 Zenopa LTD. All Rights Reserved.